Idera Pharmaceuticals Inc (IDRA)

[Citrati]

4:34 PM ET, 12/02/2014 - Briefing.com
Co announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models.
Compared to monotherapy with either agent, the combination regimen involving intratumoral injections of both agents demonstrated increased and sustained inhibition of treated and distant tumor growth. In addition, there were statistically significant increases in cytotoxic T cells against two antigens (AH1 and -gal) expressed in treated and distant tumors, respectively, for the combination therapy versus monotherapy with either agent.


http://finance.yahoo.com/news/idera-pharmaceuticals-announces-cancer-immunotherapy-213000210.html